Individualized Immunotherapy Threats Initial Head and Neck Cancer Patient
France-based Transgene announced on January 21, 2021, that the first patient with head and neck cancer had been dosed with the Company’s innovative, individualized immunotherapy, TG4050. This novel therapeutic cancer vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge Artificial Intelligence capabilities to customize each patient's treatment.
The goal of TG4050 is to provide the immune system with the information it needs to identify cancer cells and trigger a targeted immune response to treat the disease, said the company.
Prof. Jean-Pierre Delord, Director of the Claudius Regaud Institute and General Manager of the IUCT Oncopole, stated in a press release, “Each tumor has its own very specific potential immune targets. Head & neck cancer patients currently have no effective treatments to prevent recurrence of the disease, and half of these high-risk patients will relapse within the first year after initial treatment."
"TG4050 can address the medical need of these patients either as a single agent or in combination with the standard of care."